High expression of YTHDF1 and METTL3 has been reported to be associated with lower OS in cancer patients (56, 57), and YTHDF2, YTHDF1 and METTL3 were proved to be associated with sorafenib treatment and anti-PD-1 immunotherapy response in HCC (58). Here, YTHDF2 is linked to cancer.